Evidence map›Paper›PMID 42344902›Full record

ArticleFrontiers in immunology2026

Repeated-dose toxicity and immunogenicity evaluation of norovirus P particle-based rotavirus vaccine in juvenile cynomolgus monkeys.

Wei Pan, Yingjie Cheng, Xiaojing Shi, Yunxiang Chen, Cong Xu, Zhengbiao Yang, Qijiong Lu, Lei Wen, Fang Liu, Tingli Bian and 6 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Wei Pan *Key Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Yingjie Cheng *Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., R&D Department, Hefei, China.
Xiaojing ShiKey Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Yunxiang ChenKey Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Cong XuKey Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Zhengbiao YangKey Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Qijiong LuKey Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Lei WenKey Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Fang LiuKey Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Tingli BianKey Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Li QinKey Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Shuizhen PanKey Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Ying ChenKey Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Changwei WuAnhui Zhifei Longcom Biopharmaceutical Co., Ltd., R&D Department, Hefei, China.
Lijiang ZhangKey Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Hongzhong YangKey Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Rotavirus remains a major cause of mortality among young children worldwide, underscoring the urgent need for new vaccines. The present study evaluated the repeated-dose toxicity and immunogenicity of a bivalent rotavirus subunit candidate vaccine PP-P[6]/P[8]-VP8 Mix (containing equal amounts of P[6]-VP8 and P[8]-VP8 chimeric antigens) based on norovirus P particles in cynomolgus monkeys. Methods: The monkeys (5 per sex per group) were randomly assigned to a blank control group, an adjuvant control group, and low- and high-dose vaccine groups (60 μg/monkey and 120 μg/monkey). The animals received four intramuscular injections at 4-week intervals, followed by a 6-week recovery period. General behavior, body temperature, body weight, food intake, hematology, serum biochemistry, ophthalmic examination, electrocardiogram, urine analysis, immunogenicity parameters, and pathological examination of the animals were detected. Results: No toxicologically significant abnormalities were observed throughout the study. Histopathological examination showed that there were deposition foci of aluminum hydroxide adjuvant and mild subacute inflammatory reactions at the injection site in the vaccine group. Lymphoid follicle hyperplasia and lymph sinus histiocytosis were observed in the draining lymph nodes, which are typical local immune response manifestations of aluminum adjuvant vaccines. No other adverse pathological changes were found. Conclusions: Our regulatory toxicology study has demonstrated the safety and immunogenicity of PP-P[6]/P[8] - VP8 Mix under the experimental conditions, supporting its entry into clinical research.

Indexed as

Immunogenicity, VaccineNorovirusRotavirus InfectionsRotavirus VaccinesAnimalsAntibodies, ViralFemaleMacaca fascicularisMaleProtein Subunit VaccinesRotavirusAntibodies, ViralProtein Subunit VaccinesRotavirus Vaccinesbivalent rotavirus vaccinechimeric virus-like particlescynomolgus monkeysimmunogenicitynorovirus P particlerepeat-dose toxicity

Identifiers

PMID42344902
PMCPMC13286892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.